Lurie Children’s use cookies to improve your experience on our website and to show you personalized content. To find out more, read our Website Privacy Policy. By using the site and clicking on "I AGREE", you accept to the use of Cookies.
An Open-Label Safety and Efficacy Study for Patients With Nonsense Mutation Cystic Fibrosis Previously Treated With Ataluren (PTC124®)
Official Title:
An Open-Label Safety and Efficacy Study for Patients With Nonsense Mutation Cystic Fibrosis Previously Treated With Ataluren (PTC124®)
This is a Phase 3, multicenter, open-label, safety and efficacy study of ataluren in patients with nonsense mutation cystic fibrosis who participated in the previous Phase 3 study with ataluren (PTC124-GD-009-CF; Study 009).